We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FUSB:NASDAQFirst US Bancshares, Inc. Analysis

Data as of 2026-04-05 - not real-time

$15.40

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

First US Bancshares (FUSB) is trading around $15.40, comfortably above its 20‑day ($15.13) and 50‑day ($15.15) simple moving averages, while the MACD histogram remains positive and the signal line is bullish, indicating short‑term momentum support. Technical indicators such as an RSI of 55 and a clear support level at $14.71 suggest the stock is not overbought and has room to move higher toward the $15.54 resistance. Fundamentally, the company appears deeply undervalued: the discounted cash‑flow model implies a fair value near $42.6, and its price‑to‑earnings ratio of 15.4 sits below the industry average of 16.6, offering a margin of safety. The dividend yield of 1.82% with a modest 28% payout ratio, coupled with a strong cash position ($79.5M) and minimal debt, supports the sustainability of the income stream.
Despite a relatively high 30‑day volatility of 23.5%, the beta is near zero, indicating that broader market swings have limited impact on FUSB. The regional‑bank sector carries medium credit and regulatory risk, but the company’s low leverage and solid liquidity mitigate these concerns. Overall, the blend of attractive valuation, stable dividend, and supportive technical backdrop makes FUSB a compelling candidate for investors seeking value‑oriented exposure to U.S. community banks.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Price trading above short‑term moving averages
  • Bullish MACD and neutral RSI
  • Support level near $14.71

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value far exceeds current price
  • PE below industry average
  • Sustainable dividend yield

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong cash position and minimal debt
  • Low beta indicating resilience to market volatility
  • Undervalued valuation metrics with upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth10.10%
Profit Margin16.19%
P/E Ratio15.4
ROE5.87%
ROA0.53%
P/B Ratio0.8
Op. Cash Flow$12.3M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI55.3
Support$14.71
Resistance$15.54
MA 20$15.13
MA 50$15.15
MA 200$13.47
MACDBullish
VolumeIncreasing
Fear & Greed Index78.8

Valuation

Fair Value$42.56
GradeUndervalued
TypeValue
Dividend Yield1.82%

Risk Assessment

Beta0.05
Volatility23.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.